GSK to acquire Nuvalent for $124/share (~$10.6B); assets under FDA review for 2026 approval

Nuvalent, Inc.

All-share tender offer at $124.00 per share; aggregate equity value ~$10.6B; net cash investment ~$9.4B.
40% premium to last closing price; 26% premium to 30-day VWAP; no financing condition.
Deal includes late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib; FDA decisions due Sept/Nov 2026.
Supporting stockholders (~28% of Class A shares) have agreed to tender; termination fee $350.5M.
Transaction expected to close Q3 2026; GSK expects accretion to operating profit in 2027, EPS in 2029.

item 1.01 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #3 for 2026-06-09. Read digest

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nuvalent, Inc. entered into Agreement and Plan of Merger with GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc valued at $124.00 per Share (effective 2026-06-09).

Action: entry
Agreement: merger
Counterparty: GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc
Value: $124.00 per Share
Effective: 2026-06-09

Exact text from the filing

On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “ Company ” or “ Nuvalent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ”).

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-262950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.